Nanobiotix: Shares Surge 11% Following Analyst Upgrade
Nanobiotix stock rose by 10.98% to €37.20 on Friday mid-session, following a trading suspension the previous day related to a global securities offering. The French biotech leads the SBF 120, which is up 0.37%. Jefferies raised its price target from €21.50 to €60 on Friday, maintaining a 'buy' recommendation.
Jefferies Significantly Raises Price Target After Trading Resumption
Today's movement comes after yesterday's trading suspension linked to a global securities offering. The resumption session is marked by a significant analyst revaluation: Jefferies raised its target from €21.50 to €60 and reaffirmed its 'buy' opinion. The target shows a theoretical potential of 61% relative to the current price.
The stock leads the SBF 120 while the broader index gains 0.37%. This rebound comes after a challenging week, with the stock still showing a nearly 20% decline over the week. However, the performance remains spectacular over time, with a gain of more than 1,000% over a year, fueled in May by clinical announcements related to the JNJ-1900 candidate developed in partnership with Johnson & Johnson.
Stock Rebounds on its 20-Day Moving Average Amid Increased Volatility
The price moves back above its 20-day moving average at €35.08, after briefly touching it earlier in the week during a dip to €33.52. The gap to the 50-day moving average (€30.44) reaches 22.21%, indicating the persistence of a medium-term bullish dynamic despite recent consolidation. The RSI at 47 remains neutral and supports today's rebound movement without indicating any particular tension.
The one-month volatility stands at 25, consistent with ranges observed since the record high on May 18 at €47.66. The technical resistance is at €46.18, which is the recent peak that the stock will need to retest to confirm a recovery. Conversely, the support of €25.68 marks the lower end of the range in case of a reversal.
